Sarah Cannon Research Institute/SCRI is a clinical research site located in Nashville, Tennessee, United States 37203.
Crixeo Clinical Trials Trust Score: 24/100 (FAILING). This profile has not yet been claimed by the site owner.
Sarah Cannon Research Institute/SCRI has participated in 33 clinical trials with 11 currently active.
Therapeutic areas: Breast Neoplasm, Neoplasm Metastasis, Metastatic Pancreatic Cancer.
Sponsors: Eli Lilly and Company, MBQ Pharma, Loxo Oncology, Inc..
Is this your site? Claim your profile and control the information sponsors and patients see.
Browse all research sites in Tennessee · View every site in Nashville
Trust Score: 24/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.
Sarah Cannon Research Institute/SCRI has a Crixeo Trust Score of 24/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.
Sarah Cannon Research Institute/SCRI has 33 clinical trials on record, with 11 currently active. Their work covers Breast Neoplasm, Neoplasm Metastasis, Metastatic Pancreatic Cancer.
Sarah Cannon Research Institute/SCRI has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.
Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.